Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

Prajwol Pathak, MD, Athira Unnikrishnan, MD, Fei Zou, PhD, Helen Leather, BPharm, Christopher R. Cogle, MD, Jack W Hsu, MD, Randy A. Brown, MD, John R. Wingard, MD, Maxim Norkin, MD PhD

Blood (2016) 128 (22): 5832.

https://doi.org/10.1182/blood.V128.22.5832.5832

Published: 2016

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Lakshmikanth Katragadda, MD, Maxim Norkin, MD PhD, Myron Chang, PhD, Yunfeng Dai, PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Helen Leather, BPharm, Ying Li, MD PhD, Lamis K Eldjerou, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2015) 126 (23): 3221.

https://doi.org/10.1182/blood.V126.23.3221.3221

Published: 2015

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

Journal Articles

Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis

Ilicia L. Shugarman, MD, Randy A Brown, MD, Christopher R Cogle, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Maxim Norkin, MD, PhD, Helen Leather, BPharm, Xiaomin Lu, Michele W. Sugrue, John R. Wingard, MD, PhD, Jan Moreb, MD, Jack W Hsu

Blood (2013) 122 (21): 4520.

https://doi.org/10.1182/blood.V122.21.4520.4520

Published: 2013

Journal Articles

Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/ldTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma

Michael T. Byrne, DO, John R. Wingard, MD, Helen Leather, BPharm, Jan S Moreb, MD

Blood (2012) 120 (21): 4524.

https://doi.org/10.1182/blood.V120.21.4524.4524

Published: 2012

Journal Articles

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update

Michael T. Byrne, DO, Donya Salmasinia, MSc, Helen Leather, BPharm, Amy Davis, MSc, Jack W. Hsu, MD, Laura Wiggins, PharmD, Christopher R. Cogle, MD, Myron N Chang, PhD, John R. Wingard, MD, Jan S Moreb, MD

Blood (2012) 120 (21): 2023.

https://doi.org/10.1182/blood.V120.21.2023.2023

Published: 2012

Journal Articles

Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M

Christina Escobar, B.S., Sukanthini Subbiah, MD, Maxim Norkin, MD, PhD, Helen Leather, BPharm, Ashley Richards, Pharm.D., Randy A. Brown, MD, W. Stratford May, John R. Wingard, MD, Jack W Hsu, MD, Christopher R Cogle, M.D.

Blood (2011) 118 (21): 4301.

https://doi.org/10.1182/blood.V118.21.4301.4301

Published: 2011

NARROW

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis

Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/ldTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update

Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only